Fermented Oyster Extract Promotes Insulin-Like Growth Factor-1-Mediated Osteogenesis and Growth Rate

Mar Drugs. 2020 Sep 18;18(9):472. doi: 10.3390/md18090472.

Abstract

Fermented oyster (Crassostrea gigas) extract (FO) prevents ovariectomy-induced osteoporosis by inhibiting osteoclastogenesis and activating osteogenesis. However, the molecular mechanisms underlying FO-mediated bone formation and growth rate are unclear. In the current study, we found that FO significantly upregulated the expression of growth-promoting genes in zebrafish larvae including insulin-like growth factor 1 (zigf-1), insulin-like growth factor binding protein 3 (zigfbp-3), growth hormone-1 (zgh-1), growth hormone receptor-1 (zghr-1), growth hormone receptor alpha (zghra), glucokinase (zgck), and cholecystokinin (zccka). In addition, zebrafish larvae treated with 100 μg/mL FO increased in total body length (3.89 ± 0.13 mm) at 12 days post fertilization (dpf) compared to untreated larvae (3.69 ± 0.02 mm); this effect was comparable to that of the β-glycerophosphate-treated zebrafish larvae (4.00 ± 0.02 mm). Furthermore, FO time- and dose-dependently increased the extracellular release of IGF-1 from preosteoblast MC3T3-E1 cells, which was accompanied by high expression of IGF-1. Pharmacological inhibition of IGF-1 receptor (IGF-1R) using picropodophyllin (PPP) significantly reduced FO-mediated vertebrae formation (from 9.19 ± 0.31 to 5.53 ± 0.35) and growth performance (from 3.91 ± 0.02 to 3.69 ± 0.01 mm) in zebrafish larvae at 9 dpf. Similarly, PPP significantly decreased FO-induced calcium deposition in MC3T3-E1 cells by inhibiting GSK-3β phosphorylation at Ser9. Additionally, DOI hydrochloride, a potent stabilizer of GSK-3β, reduced FO-induced nuclear translocation of RUNX2. Transient knockdown of IGF-1Rα/β using specific silencing RNA also resulted in a significant decrease in calcium deposition and reduction in GSK-3β phosphorylation at Ser9 in MC3T3-E1 cells. Altogether, these results indicate that FO increased phosphorylated GSK-3β at Ser9 by activating the autocrine IGF-1-mediated IGF-1R signaling pathway, thereby promoting osteogenesis and growth performance. Therefore, FO is a potential nutritional supplement for bone formation and growth.

Keywords: Crassostrea gigas; GSK-3β; IGF-1; RUNX2; growth performance; osteogenesis.

Publication types

  • Comparative Study

MeSH terms

  • 3T3 Cells
  • Animals
  • Calcium / metabolism
  • Crassostrea / chemistry*
  • Dose-Response Relationship, Drug
  • Fermentation
  • Gene Knockdown Techniques
  • Glycerophosphates / pharmacology
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Insulin-Like Growth Factor I / genetics
  • Insulin-Like Growth Factor I / metabolism
  • Mice
  • Osteogenesis / drug effects*
  • Phosphorylation / drug effects
  • Somatomedins / genetics
  • Somatomedins / metabolism*
  • Time Factors
  • Tissue Extracts / isolation & purification
  • Tissue Extracts / pharmacology*
  • Up-Regulation / drug effects
  • Zebrafish
  • Zebrafish Proteins / genetics
  • Zebrafish Proteins / metabolism*

Substances

  • Glycerophosphates
  • Somatomedins
  • Tissue Extracts
  • Zebrafish Proteins
  • igf1 protein, zebrafish
  • Insulin-Like Growth Factor I
  • Glycogen Synthase Kinase 3 beta
  • Calcium
  • beta-glycerophosphoric acid